Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, Phase III trial-Reference-Cited by-同舟云学术

Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, Phase III trial

Published:2014-12 Issue:12 Volume:24 Page:1861-1872
ISSN:0924-977X
Container-title:European Neuropsychopharmacology
language:en
Short-container-title:European Neuropsychopharmacology

Author:

Hervas Amaia,Huss Michael^ORCID,Johnson Mats,McNicholas Fiona,van Stralen Judy,Sreckovic Sasha,Lyne Andrew,Bloomfield Ralph,Sikirica Vanja,Robertson Brigitte

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology

Reference54 articles.

2. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine;Bangs;J. Am. Acad. Child Adolesc. Psychiatry,2008

3. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation;Barkley;Pediatrics,1990

4. Attention-deficit hyperactivity disorder;Biederman;Lancet,2005

5. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD;Biederman;CNS Spectr.,2008

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatments for ADHD in Children and Adolescents: A Systematic Review;Pediatrics;2024-03-25

2. Alpha-2 Agonists in Children and Adolescents With Post-traumatic Stress Disorder: A Systematic Review;Cureus;2024-01-26

3. The Dose-Response Relationship of Atomoxetine for the Treatment of Children With ADHD: A Systematic Review and Dose-Response Meta-Analysis of Double-Blind Randomized Placebo-Controlled Trials;Journal of Attention Disorders;2023-12-08

4. The Role of Alpha-2 Agonists for Attention Deficit Hyperactivity Disorder in Children: A Review;Neurology International;2023-05-22

5. Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung;Neuro-/Psychopharmaka im Kindes- und Jugendalter;2023